Search results
Showing results for
Bioarchitech, Oxford, UK, an immuno-oncology therapeutics start-up company announces that it has secured a material license from the European Collection of Authenticated Cell Cultures (ECACC), UKHSA for a mammalian cell line to be developed as a scalable and high yield viral manufacturing platform and for the vector backbone of BA-V151, a preclinical stage candidate being developed as a treatment for metastatic cancers.
“The BioEscalator is more than just an innovation centre, it’s a true community.”
Ana Carolina Borges, Alethio Therapeutics
“The advice and insights of experienced peers and the knowledge and network built through BioEscalator events have been hugely beneficial.”
Aneesh Aggarwal and Sooraj Achar, Akimbo Bio
“The BioEscalator brings together an exceptional mix of innovation, ambition and entrepreneurial spirit.”
Frederik Lassen, Omos Biosciences
“The facilities and support teams enabled us to focus on R&D rather than operational maintenance.”
Atherton Mutombwera, Hutano Diagnostics
“The support and flexibility from the BioEscalator team was invaluable throughout our growth journey.”
Hollie Coe, Base Genomics (now Exact Sciences Innovation)
“The BioEscalator team have been incredibly supportive over the course of our journey.”
Charlotte Casebourne, Theolytics
Accessibility Statement
The University of Oxford is committed to providing an accessible web presence that gives members of the public and members of the University community full access to University information, courses and activities offered publicly through the web. Our Equality Policy outlines our commitment to a culture which ‘maintains a working, learning and social environment in which the rights and dignity of all its staff and students are respected’.